Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

Author's Avatar
Nov 10, 2022

New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options